{"organizations": [], "uuid": "d962c48cf33df139181adb3705d1bcbaf7436937", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-abbvie-qtrly-shr-003-qtrly-adj-shr/brief-abbvie-qtrly-shr-0-03-qtrly-adj-shr-1-48-idUSB8N1LI039", "country": "US", "domain_rank": 408, "title": "BRIEF-Abbvie Qtrly Shr $0.03, Qtrly Adj Shr $1.48", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-26T14:58:00.000+02:00", "replies_count": 0, "uuid": "d962c48cf33df139181adb3705d1bcbaf7436937"}, "author": "", "url": "https://www.reuters.com/article/brief-abbvie-qtrly-shr-003-qtrly-adj-shr/brief-abbvie-qtrly-shr-0-03-qtrly-adj-shr-1-48-idUSB8N1LI039", "ord_in_thread": 0, "title": "BRIEF-Abbvie Qtrly Shr $0.03, Qtrly Adj Shr $1.48", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "humira", "sentiment": "none"}], "organizations": [{"name": "reuters staff", "sentiment": "negative"}, {"name": "abbvie inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 01 PM / Updated 11 minutes ago BRIEF-Abbvie Qtrly Shr $0.03, Qtrly Adj Shr $1.48 Reuters Staff 2 Min Read \nJan 26 (Reuters) - Abbvie Inc: \n* ABBVIE - QTRLY EARNINGS PER SHARE $0.03; QTRLY ADJUSTED EARNINGS PER SHARE $1.48; QTRLY ADJUSTED NET REVENUES $7.739 BILLION, UP 14.1 PERCENT ON REPORTED BASIS \n* ABBVIE INC Q4 EARNINGS PER SHARE VIEW $1.44, REVENUE VIEW $7.53 BILLION -- THOMSON REUTERS I/B/E/S \n* ABBVIE - SEES 2018 GAAP DILUTED EPS OF $6.45 TO $6.55; RAISES 2018 ADJUSTED EARNINGS PER SHARE GUIDANCE TO $7.33 TO $7.43 * ABBVIE - SEES 2018 REVENUE APPROACHING $32 BILLION \n* ABBVIE INC FY2018 EARNINGS PER SHARE VIEW $6.59, REVENUE VIEW $31.04 BILLION -- THOMSON REUTERS I/B/E/S \n* ABBVIE - QTRLY TOTAL HUMIRA SALES $4,892 MILLION, UP 14 PERCENT ON REPORTED BASIS \n* ABBVIE - QTRLY TOTAL IMBRUVICA SALES $708 MILLION, UP 38.7 PERCENT ON REPORTED BASIS \n* ABBVIE - PLANS TO MAKE INVESTMENTS OF ABOUT $2.5 BILLION OVER NEXT 5 YEARS IN CAPITAL PROJECTS IN U.S. \n* ABBVIE - CURRENTLY EVALUATING ADDITIONAL EXPANSION OF ITS U.S. FACILITIES \n* ABBVIE - RESULTS FOR 2017 REFLECTED NET CHARGE OF $0.77 PER SHARE RELATED TO U.S. TAX REFORMS \n* ABBVIE - NET CHARGE OF $0.77/SHARE INCLUDED ONE-TIME IMPACT OF ABOUT $4.5 BILLION FOR MANDATORY TAXATION ON PREVIOUSLY UNREPATRIATED EARNINGS \n* ABBVIE - IN 2018, CO WILL EXPERIENCE ONE-TIME NET TAX BENEFIT RELATED TO TIMING OF PHASE IN OF PROVISIONS OF NEW LEGISLATION ON CERTAIN UNITS \n* ABBVIE - PLANS TO ACCELERATE PENSION FUNDING BY $750 MILLION, ENHANCE NON-EXECUTIVE EMPLOYEE COMPENSATION Source text for Eikon:  ", "external_links": [], "published": "2018-01-26T14:58:00.000+02:00", "crawled": "2018-01-26T15:16:54.010+02:00", "highlightTitle": ""}